The management of mevalonate kinase deficiency, the genetic cause of Hyperimmunoglobulin D Syndrome, has been transformed by advances in autoinflammatory disease therapy. Mevalonate kinase deficiency leads to the accumulation of mevalonic acid and the subsequent inflammatory response characteristic of HIDS. The Hyperimmunoglobulin D Syndrome Treatment Market is experiencing...
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek